愛美客(300896.SZ):2021年歸母淨利潤升117.81%至9.58億元 擬10派21元
格隆匯3月7日丨愛美客(300896.SZ)披露2021年年度報吿,報吿期內,公司實現營業收入14.48億元,同比增長104.13%;利潤總額11.22億元,同比增長123.18%;歸屬於上市公司股東的淨利潤9.58億元,同比增長117.81%;基本每股收益4.43元,年報推10股派發現金紅利21.00元(含税)。
公司各產品在生物醫用材料的應用、配方組分、核心技術運用上有所不同,經過前期的市場培育,產品安全性和有效性得到了下游醫療機構以及終端消費者的充分認可。報吿期內,公司產品線實現全面增長。其中,溶液類注射產品實現營業收入10.46億元,同比增長133.84%;凝膠類注射產品實現營業收入3.85億元,同比增長52.80%。受益於近年來消費者對抗衰老、皮膚年輕化的需求不斷增長,以嗨體為核心的溶液類注射產品增長幅度更大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.